The ASH 2018 conference in San Diego featured a number of exciting new studies with clinical relevance for the treatment of patients with acute myeloid leukemia (AML). The key studies that are discussed here are grouped in 3 broad treatment groups: targeted therapies, immunotherapy and allogeneic stem cell transplantation (allo SCT).

(BELG J HEMATOL 2019;10(1):36–40)